ClinicalTrials.gg
RecruitingNCT07748858PPC HeartUpdated Aug 6, 2026

Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities

An observational study in Cardiovascular, Comorbidity and Diabetes, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by University of Alabama at Birmingham · Observational

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
29
Ages
50 Years to 99 Years
Sex
All
01

Study summary

This is formative evaluation trial guided by the Values Clarification Theory25 and the Cultural Values Theory26, with specific aims to: Aim 1. Develop a culturally appropriate version of the PPC Approach for older AAs with CVCs by assembling a community advisory group of 3 primary care clinicians, 3 older AA patients with CVCs, and 3 AA persons who care for AA patients with CVCs to solicit feedback on the PPC Approach. Aim 2. Determine the acceptability (e.g., program appraisal interviews) and feasibility (e.g., avg. length of program sessions, program participation rate, study completion rate) of the PPC Approach among a sample 20 of under-resourced older southern AA patients with CVCs receiving primary care at Cooper Green Mercy Health Services Authority. Aim 3. Examine the ability of participants to complete pre- and post-test (8 weeks post-baseline) measures of perception of care, treatment burden, shared decision-making, and patient-clinician communication exchange.

02

Conditions studied

  • Cardiovascular
  • Comorbidity
  • Diabetes
  • Inflammatory Joint Diseases
  • Chronic Kidney Diease
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cardiovascular Disease

Keywords

  • Cardiovascular Diseases
  • Chronic Kidney Disease
  • Chronic Obstructive Pulmonary Disease
  • Patient-Centered Care
  • Shared Decision Making
  • Care Coordination
  • Older Adults
  • Multiple Chronic Conditions
03

In context

Diabetes Mellitus

8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.

This study's planned enrollment of 29 is below the median of 246 across 1,936 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cooper Green Mercy Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • greater than or equal to 50 years old
  • at least one CVD (i.e., coronary artery disease, hypertension, heart failure, arrhythmias, cardiomyopathy, peripheral artery disease, stroke, and valvular heart disease)
  • at least one coexisting chronic condition (i.e., inflammatory joint disease, /asthma, diabetes, chronic kidney disease, and cancer one-year post-treatment)
  • a caregiver of a participant, or a provider who serves this population.

Exclusion criteria

Exclusion Criteria:

  • Axis I psychiatric (schizophrenia, bipolar disorder), dementia, suicidal ideation,
  • active substance use disorder nursing home or assisted living facility residence.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
29 participants (estimated)
Patient registry
No

Groups and cohorts

  • Community Advisory Group (CAG) and Pilot Group

    Nine of the 29 participants will participate in Aim 1 of the study, which involves convening a focus group to develop a culturally responsive version of the PPC Approach for underserved African Americans. This number was determined based on qualitative research best practices, which suggest that 6-10 participants per focus group allow for a diverse range of perspectives while maintaining an environment conducive to in-depth discussion. Additionally, this sample size aligns with previous studies that successfully used small, targeted focus groups to refine culturally tailored interventions. Twenty patients will participate in the pilot testing of the newly developed culturally responsive version of the PPC Approach. This number was determined to be satisfactory because it provides a sufficient sample to assess the feasibility and acceptability of the intervention while ensuring a manageable study scope. Prior feasibility studies have demonstrated that sample sizes between 15 and 30 par

06

What researchers measure

Primary outcomes

  1. Older Patient Assessment of Chronic Illness Care (O-PACIC) Score

    Patient experience with integrated care delivery and self-management support measured using the 10-item Older Patient Assessment of Chronic Illness Care (O-PACIC) questionnaire. Responses to the 10 items will be summed to calculate a total score ranging from 10 to 50. Higher scores indicate more positive perceptions of chronic illness care. Scores will be reported at baseline and 8 weeks post-baseline, along with the change from baseline.

    Time frame: Baseline and eight weeks post- baseline.

Secondary outcomes

  1. Treatment Burden Questionnaire (TBQ) Score

    Perceived treatment burden measured using the 13-item Treatment Burden Questionnaire (TBQ). Each item is rated from 0, indicating not a problem, to 10, indicating a big problem. Item scores will be summed to calculate a total score ranging from 0 to 130. Higher scores indicate greater perceived treatment burden. Scores will be reported at baseline and 8 weeks post-baseline, along with the change from baseline.

    Time frame: Baseline and eight weeks post- baseline

  2. Perceived Shared Clinical Decision-Making (CollaboRATE Score)

    Patient perception of involvement in shared decision-making measured using the 3-item CollaboRATE questionnaire. Responses to the three items will be averaged to calculate an overall mean score ranging from 1 to 9. Higher scores indicate greater perceived involvement in shared decision-making. Scores will be assessed at baseline and 8 weeks post-baseline, and change from baseline will be evaluated.

    Time frame: Baseline and eight week post- baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data from this small pilot study will not be shared with other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07748858
Responsible party
Deborah Ejem (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 6, 2026
Start date
May 1, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Nardakafaria McNeill
Contact
nmcneill@uab.edu
205-934-0707
Deborah Ejem
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion